| Similar Articles |
|---|
 |
The Motley Fool
September 29, 2006
Brian Lawler |
The Long Road Ahead for ViroPharma Faced with the threat of generic competition, the company focuses its efforts on a new drug. ViroPharma investors should watch intently.   |
The Motley Fool
November 18, 2005
Stephen D. Simpson |
International Superstar Stocks: Telecoms Here is information highlighting some of the risks and rewards related to international investing. Perhaps a few international superstar stocks will be uncovered in the process: Telecoms. |
The Motley Fool
January 9, 2007
Brian Lawler |
ViroPharma's Healthy Sales Guidance The coming year looks like another strong one for the drug developer. This small-cap pharmaceutical stock is worth taking a look at just for its cheap valuation. |
The Motley Fool
May 7, 2007
Brian Lawler |
ViroPharma Victorious A strong first quarter helps the pharmaceutical storm into 2007. Investors, take note. |
The Motley Fool
September 9, 2005
Seth Jayson |
A Stellar Way to Lose Money Satellite-radio provider WorldSpace is burning through the money, but at least the managers won't go hungry. If you're looking for a good investment, look elsewhere. |
The Motley Fool
November 3, 2006
Brian Lawler |
Nothing's Wrong With ViroPharma Despite potential generic competition on the horizon, the company is going strong. Vancocin's fate will determine how well shares of ViroPharma perform in the near future. |
The Motley Fool
February 9, 2009
Brian Orelli |
ViroPharma Cut in Half ViroPharma's phase 3 drug, maribavir, failed to show an effect in reducing cytomegalovirus (CMV) disease in stem cell transplant patients, and the stock gets axed in half. |
The Motley Fool
April 30, 2008
Brian Lawler |
ViroPharma: Risky and Exciting Solid lead drug, meet promising pipeline candidate. |
The Motley Fool
February 1, 2006
Tim Hanson |
The Truth About Telecom Many investors have left telecom for dead. Don't make that same mistake. Tread carefully in these waters, and remember that cash is king and foreign lands shouldn't be overlooked. |
The Motley Fool
November 24, 2010
Sean Williams |
ViroPharma: Bargain or Value Trap? Generic competition and production issues are major red flags. |
The Motley Fool
December 9, 2004
Seth Jayson |
Don't Fear the Foreigners Cast your net offshore if you want to expand your investing horizons. A little bit of expatriate curiosity can help your portfolio's returns. |
The Motley Fool
March 17, 2006
Rick Aristotle Munarriz |
WorldSpace Oddity The international satellite radio provider is growing -- but not fast enough. As much as India's economy is likely to grow, WorldSpace's bottom-heavy balance sheet doesn't grant it the luxury of patience. |
The Motley Fool
February 28, 2008
Brian Lawler |
ViroPharma in Check Sales of its antibiotic are slowing down, but there is a promising drug in its pipeline. |
The Motley Fool
November 27, 2009
Brian Orelli |
Biotech Bargains for Your Portfolio Everyone is looking for bargains this time of year. That includes pharmaceutical giants looking to pick up some biotechs on the discount rack, and investors trying to get there first. |
The Motley Fool
April 14, 2005
Seth Jayson |
Should You Get Religion? True Religion Apparel has been tearing up the charts, but will there be anything left for investors? |
The Motley Fool
February 4, 2008
Tony Arsta |
Best International Stock: Sadia A quick summary of Brazilian food producer Sadia. |
The Motley Fool
August 9, 2005
Seth Jayson |
Terrorist in Your Portfolio? Wall Street is making a lot of noise about the alleged terrorist ties of satellite radio provider WorldSpace's backers. That's the least of the company's troubles. The smart money here looks like a short, or no position at all. |
The Motley Fool
October 12, 2011
Eric Bleeker |
What Telecom Investors Need to Watch This Earnings Season Cash flows will be on every telecom investor's mind. |
